Cytokine effects on the basal ganglia and dopamine function: The subcortical source of inflammatory malaise

[1]  D. F. Drake,et al.  Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. , 2012, Archives of general psychiatry.

[2]  B. Trapp,et al.  Lipopolysaccharide-Induced Microglial Activation and Neuroprotection against Experimental Brain Injury Is Independent of Hematogenous TLR4 , 2012, The Journal of Neuroscience.

[3]  R. Schwarcz,et al.  Kynurenines in the mammalian brain: when physiology meets pathology , 2012, Nature Reviews Neuroscience.

[4]  A. Abi-Dargham,et al.  Dopamine Release in Chronic Cannabis Users: A [11C]Raclopride Positron Emission Tomography Study , 2012, Biological Psychiatry.

[5]  C. Whitley,et al.  START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients. , 2012, Molecular genetics and metabolism.

[6]  Anil Kumar,et al.  Methamphetamine toxicity and its implications during HIV-1 infection , 2011, Journal of NeuroVirology.

[7]  P. Barberger‐Gateau,et al.  Chronic Low-Grade Inflammation in Elderly Persons Is Associated with Altered Tryptophan and Tyrosine Metabolism: Role in Neuropsychiatric Symptoms , 2011, Biological Psychiatry.

[8]  C. Matute.  Glutamate and ATP signalling in white matter pathology , 2011, Journal of anatomy.

[9]  T. Wichmann,et al.  Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. , 2011, Brain : a journal of neurology.

[10]  Andrew H. Miller,et al.  Immune system to brain signaling: neuropsychopharmacological implications. , 2011, Pharmacology & therapeutics.

[11]  Inbal Goshen,et al.  Immune modulation of learning, memory, neural plasticity and neurogenesis , 2011, Brain, Behavior, and Immunity.

[12]  D. Rye,et al.  Chronic Interferon-Alpha Administration Disrupts Sleep Continuity and Depth in Patients with Hepatitis C: Association with Fatigue, Motor Slowing, and Increased Evening Cortisol , 2010, Biological Psychiatry.

[13]  D. Dougherty,et al.  A Positron Emission Tomography Study Examining The Dopaminergic Activity of Armodafinil in Adults Using [11C]Altropane and [11C]Raclopride , 2010, Biological Psychiatry.

[14]  Elliot T. Berkman,et al.  Inflammation-Induced Anhedonia: Endotoxin Reduces Ventral Striatum Responses to Reward , 2010, Biological Psychiatry.

[15]  B. Burton,et al.  Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU). , 2010, Molecular genetics and metabolism.

[16]  N. Quan,et al.  Location-specific activation of the paraventricular nucleus of the hypothalamus by localized inflammation , 2010, Brain, Behavior, and Immunity.

[17]  K. Channon,et al.  Tetrahydrobiopterin: pleiotropic roles in cardiovascular pathophysiology , 2010, Heart.

[18]  R. Blakely,et al.  Interleukin-1 Receptor Activation by Systemic Lipopolysaccharide Induces Behavioral Despair Linked to MAPK Regulation of CNS Serotonin Transporters , 2010, Neuropsychopharmacology.

[19]  J. Sloan,et al.  Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Fava,et al.  S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. , 2010, The American journal of psychiatry.

[21]  A. Machado,et al.  Effect of in vivo striatal perfusion of lipopolysaccharide on dopamine metabolites , 2010, Neuroscience Letters.

[22]  R. Schwarcz,et al.  Reduction of Endogenous Kynurenic Acid Formation Enhances Extracellular Glutamate, Hippocampal Plasticity, and Cognitive Behavior , 2010, Neuropsychopharmacology.

[23]  N. Herrmann,et al.  A Meta-Analysis of Cytokines in Major Depression , 2010, Biological Psychiatry.

[24]  W. Banks,et al.  The blood–brain barrier and immune function and dysfunction , 2010, Neurobiology of Disease.

[25]  S. Rutella,et al.  Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds , 2010, Expert opinion on therapeutic patents.

[26]  Yang Liu,et al.  A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone , 2010, Proceedings of the National Academy of Sciences.

[27]  D. Charney,et al.  Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression , 2010, Biological Psychiatry.

[28]  Aurélien Grosdidier,et al.  Rational design of indoleamine 2,3-dioxygenase inhibitors. , 2010, Journal of medicinal chemistry.

[29]  Bozena Kaminska,et al.  MAPK Signal Transduction Underlying Brain Inflammation and Gliosis as Therapeutic Target , 2009, Anatomical record.

[30]  Philip D. Harvey,et al.  Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? , 2009, Journal of affective disorders.

[31]  R. Dantzer,et al.  CSF Concentrations of Brain Tryptophan and Kynurenines during Immune Stimulation with IFN-alpha: Relationship to CNS Immune Responses and Depression , 2009, Molecular Psychiatry.

[32]  Paul Cumming,et al.  PET Studies of Cerebral Levodopa Metabolism: A Review of Clinical Findings and Modeling Approaches , 2009, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[33]  D. Charney,et al.  Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression , 2009, Biological Psychiatry.

[34]  R. Dantzer,et al.  Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice , 2009, Molecular Psychiatry.

[35]  Charles L. Raison,et al.  Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression , 2009, Biological Psychiatry.

[36]  G. Miller,et al.  Protective Actions of the Vesicular Monoamine Transporter 2 (VMAT2) in Monoaminergic Neurons , 2009, Molecular Neurobiology.

[37]  R. Dantzer,et al.  Induction of IDO by Bacille Calmette-Guérin Is Responsible for Development of Murine Depressive-Like Behavior1 , 2009, The Journal of Immunology.

[38]  M. Swain,et al.  Cerebral Microglia Recruit Monocytes into the Brain in Response to Tumor Necrosis Factorα Signaling during Peripheral Organ Inflammation , 2009, The Journal of Neuroscience.

[39]  D. F. Drake,et al.  Activation of Central Nervous System Inflammatory Pathways by Interferon-Alpha: Relationship to Monoamines and Depression , 2009, Biological Psychiatry.

[40]  Andrew H. Miller.  Mechanisms of cytokine-induced behavioral changes: Psychoneuroimmunology at the translational interface , 2009, Brain, Behavior, and Immunity.

[41]  D. Scheible,et al.  Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria , 2009, Journal of Inherited Metabolic Disease.

[42]  N. Blau,et al.  Effect of BH4 supplementation on phenylalanine tolerance , 2009, Journal of Inherited Metabolic Disease.

[43]  Alan L. Miller,et al.  The methylation, neurotransmitter, and antioxidant connections between folate and depression. , 2008, Alternative medicine review : a journal of clinical therapeutic.

[44]  D. Fuchs,et al.  Chronic immune stimulation correlates with reduced phenylalanine turnover. , 2008, Current drug metabolism.

[45]  G. Miller,et al.  PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity , 2008, Neuropeptides.

[46]  G. Pagnoni,et al.  IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C , 2008, Brain, Behavior, and Immunity.

[47]  M. Ferris,et al.  Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: Current status of dopamine system vulnerability in NeuroAIDS , 2008, Neuroscience & Biobehavioral Reviews.

[48]  M. Colombo,et al.  Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism. , 2008, European journal of internal medicine.

[49]  H. Critchley,et al.  Peripheral Inflammation is Associated with Altered Substantia Nigra Activity and Psychomotor Slowing in Humans , 2008, Biological Psychiatry.

[50]  I. Tannock,et al.  A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer , 2008, Supportive Care in Cancer.

[51]  H. Anisman,et al.  Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: Comorbidity between depression and neurodegenerative disorders , 2008, Progress in Neurobiology.

[52]  R. Thorne,et al.  Delivery of interferon-β to the monkey nervous system following intranasal administration , 2008, Neuroscience.

[53]  I. Campbell,et al.  Systemic interferon-α regulates interferon-stimulated genes in the central nervous system , 2008, Molecular Psychiatry.

[54]  T. Ida,et al.  Cytokine-induced enhancement of calcium-dependent glutamate release from astrocytes mediated by nitric oxide , 2008, Neuroscience Letters.

[55]  S. Ancoli-Israel,et al.  Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  N. Kalin,et al.  Effects of Interferon-Alpha on Rhesus Monkeys: A Nonhuman Primate Model of Cytokine-Induced Depression , 2007, Biological Psychiatry.

[57]  K. Hashimoto,et al.  Increased Levels of Glutamate in Brains from Patients with Mood Disorders , 2007, Biological Psychiatry.

[58]  E. Shaw,et al.  A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. , 2007, International journal of radiation oncology, biology, physics.

[59]  G. Pagnoni,et al.  Basal Ganglia Hypermetabolism and Symptoms of Fatigue during Interferon-α Therapy , 2007, Neuropsychopharmacology.

[60]  S. Stahl.  Novel Therapeutics for Depression: L-methylfolate as a Trimonoamine Modulator and Antidepressant-Augmenting Agent , 2007, CNS Spectrums.

[61]  J. Zweier,et al.  Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4 , 2007, Proceedings of the National Academy of Sciences.

[62]  M. O’Banion,et al.  Chronic Interleukin-1β Expression in Mouse Brain Leads to Leukocyte Infiltration and Neutrophil-Independent Blood–Brain Barrier Permeability without Overt Neurodegeneration , 2007, The Journal of Neuroscience.

[63]  Sébastien Tilleux,et al.  Neuroinflammation and regulation of glial glutamate uptake in neurological disorders , 2007, Journal of neuroscience research.

[64]  T. Sheldon,et al.  Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity , 2007, Journal of Epidemiology and Community Health.

[65]  R. Dantzer,et al.  Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior , 2007, Psychoneuroendocrinology.

[66]  F. Crews,et al.  Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration , 2007, Glia.

[67]  A. Solari,et al.  Amantadine for fatigue in multiple sclerosis. , 2007, The Cochrane database of systematic reviews.

[68]  P. Hauser,et al.  Administration of pegylated interferon-α-2a or -2b does not induce sickness behavior in Lewis rats , 2006, Psychoneuroendocrinology.

[69]  Hai-Gwo Hwu,et al.  Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. , 2006, American journal of epidemiology.

[70]  P. Hauser,et al.  Can rodents be used to model interferon-α-induced depressive symptoms? , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[71]  B. Gelman,et al.  Abnormal Striatal Dopaminergic Synapses in National NeuroAIDS Tissue Consortium Subjects with HIV Encephalitis , 2006, Journal of Neuroimmune Pharmacology.

[72]  M. Yokoyama,et al.  Chronic intraperitoneal injection of interferon‐α reduces serotonin levels in various regions of rat brain, but does not change levels of serotonin transporter mRNA, nitrite or nitrate , 2006, Psychiatry and clinical neurosciences.

[73]  A. Dunn.  Effects of cytokines and infections on brain neurochemistry , 2006, Clinical Neuroscience Research.

[74]  G. Carmignoto,et al.  Astrocyte control of synaptic transmission and neurovascular coupling. , 2006, Physiological reviews.

[75]  G. Hanson,et al.  Mechanisms of methamphetamine-induced dopaminergic neurotoxicity , 2006, The AAPS Journal.

[76]  W. Cass,et al.  Involvement of cytokines in human immunodeficiency virus-1 protein Tat and methamphetamine interactions in the striatum , 2006, Experimental Neurology.

[77]  C. Song,et al.  The comparison of changes in behavior, neurochemistry, endocrine, and immune functions after different routes, doses and durations of administrations of IL-1beta in rats. , 2006, Pharmacopsychiatry.

[78]  Jing-shi Tang,et al.  μ- but not δ- and κ-opioid receptor mediates the nucleus submedius interferon-α-evoked antinociception in the rat , 2006, Neuroscience Letters.

[79]  M. Caligiuri,et al.  Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  M. Takemura,et al.  The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of s , 2006, Journal of biochemistry.

[81]  C. Barcia,et al.  Fms-Like Tyrosine Kinase 3 Ligand Recruits Plasmacytoid Dendritic Cells to the Brain1 , 2006, The Journal of Immunology.

[82]  Albert Gjedde,et al.  Dopamine Storage Capacity in Caudate and Putamen of Patients with Early Parkinson's Disease: Correlation with Asymmetry of Motor Symptoms , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[83]  R. Blakely,et al.  The Proinflammatory Cytokines Interleukin-1beta and Tumor Necrosis Factor-Alpha Activate Serotonin Transporters , 2006, Neuropsychopharmacology.

[84]  C. Matute,et al.  Glutamate‐mediated glial injury: Mechanisms and clinical importance , 2006, Glia.

[85]  R. Dantzer,et al.  Signaling pathways of interleukin-1 actions in the brain: Anatomical distribution of phospho-ERK1/2 in the brain of rat treated systemically with interleukin-1β , 2005, Neuroscience.

[86]  A. Dunn,et al.  Cytokines as mediators of depression: What can we learn from animal studies? , 2005, Neuroscience & Biobehavioral Reviews.

[87]  B. Brew,et al.  Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus , 2005, Neuropathology and applied neurobiology.

[88]  B. Brew,et al.  Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex , 2005, Journal of Neuroinflammation.

[89]  R. Keep,et al.  Monocyte Chemoattractant Protein-1 Regulation of Blood–Brain Barrier Permeability , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[90]  R. Blakely,et al.  p38 MAPK Activation Elevates Serotonin Transport Activity via a Trafficking-independent, Protein Phosphatase 2A-dependent Process* , 2005, Journal of Biological Chemistry.

[91]  M. Clanet,et al.  Modafinil for fatigue in MS , 2005, Neurology.

[92]  D. Souza,et al.  In vivo Quinolinic Acid Increases Synaptosomal Glutamate Release in Rats: Reversal by Guanosine , 2005, Neurochemical Research.

[93]  C. Nemeroff,et al.  Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. , 2005, The Journal of clinical psychiatry.

[94]  Andrew H. Miller,et al.  Cytokines and psychopathology: Lessons from interferon-α , 2004, Biological Psychiatry.

[95]  Shigeo Kobayashi,et al.  Signaling the brain in inflammation: the role of endothelial cells. , 2004, Frontiers in bioscience : a journal and virtual library.

[96]  M. Fava,et al.  Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. , 2004, The Journal of clinical psychiatry.

[97]  M. Fava,et al.  Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. , 2004, The Journal of clinical psychiatry.

[98]  C. Dinarello.  Review: Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed , 2004, Journal of endotoxin research.

[99]  T. Nagatsu,et al.  Changes in the Concentrations of Tetrahydrobiopterin, the Cofactor of Tyrosine Hydroxylase, in Blood under Physical Stress and in Depression , 2004, Annals of the New York Academy of Sciences.

[100]  R. Dantzer,et al.  Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy , 2004, Brain, Behavior, and Immunity.

[101]  A. Blomqvist,et al.  Rat brain vascular distribution of interleukin‐1 type‐1 receptor immunoreactivity: Relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli , 2004, The Journal of comparative neurology.

[102]  P. Flynn,et al.  Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  E. Park,et al.  Curcumin Suppresses Janus Kinase-STAT Inflammatory Signaling through Activation of Src Homology 2 Domain-Containing Tyrosine Phosphatase 2 in Brain Microglia 1 , 2003, The Journal of Immunology.

[104]  R. Dantzer,et al.  Nuclear factor κB nuclear translocation as a crucial marker of brain response to interleukin‐1. A study in rat and interleukin‐1 type I deficient mouse , 2003, Journal of neurochemistry.

[105]  C. Nemeroff,et al.  Interferon-alpha–induced changes in tryptophan metabolism relationship to depression and paroxetine treatment , 2003, Biological Psychiatry.

[106]  J. Javitch,et al.  Mitogen-Activated Protein Kinase Regulates Dopamine Transporter Surface Expression and Dopamine Transport Capacity , 2003, The Journal of Neuroscience.

[107]  J. Boehm,et al.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases , 2003, Nature Reviews Drug Discovery.

[108]  J. Pedraza-Chaverri,et al.  Copper blocks quinolinic acid neurotoxicity in rats: contribution of antioxidant systems. , 2003, Free radical biology & medicine.

[109]  W. Woodward,et al.  Regulation of noradrenergic function by inflammatory cytokines and depolarization , 2003, Journal of neurochemistry.

[110]  W. Banks,et al.  Entry of Blood-Borne Cytokines into the Central Nervous System: Effects on Cognitive Processes , 2003, Neuroimmunomodulation.

[111]  Kiyofumi Yamada,et al.  Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood–brain barrier , 2003, Brain Research.

[112]  C. Nemeroff,et al.  Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. , 2003, The American journal of psychiatry.

[113]  P. Brown.  Oscillations in the Basal Ganglia , 2003 .

[114]  D. A. Ciraulo.  Neuropsychopharmacology: The Fifth Generation of Progress , 2003 .

[115]  N. Clipstone,et al.  Infection with Theiler's Murine Encephalomyelitis Virus Directly Induces Proinflammatory Cytokines in Primary Astrocytes via NF-κB Activation: Potential Role for the Initiation of Demyelinating Disease , 2003, Journal of Virology.

[116]  W. Pan,et al.  Interactions of cytokines with the blood-brain barrier: implications for feeding. , 2003, Current pharmaceutical design.

[117]  H. Anisman,et al.  Cytokines, stress and depressive illness: brain‐immune interactions , 2003, Annals of medicine.

[118]  Bin Liu,et al.  Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention , 2003, Journal of Pharmacology and Experimental Therapeutics.

[119]  U. Hanisch,et al.  Microglia as a source and target of cytokines , 2002, Glia.

[120]  R. Schwarcz,et al.  Manipulation of Brain Kynurenines: Glial Targets, Neuronal Effects, and Clinical Opportunities , 2002, Journal of Pharmacology and Experimental Therapeutics.

[121]  P. Neveu,et al.  Treatment of cytokine-induced depression , 2002, Brain, Behavior, and Immunity.

[122]  R. Dantzer,et al.  The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen , 2002, Brain, Behavior, and Immunity.

[123]  Patricia A. Ganz,et al.  Fatigue and Proinflammatory Cytokine Activity in Breast Cancer Survivors , 2002, Psychosomatic medicine.

[124]  M. Rupp,et al.  Modafinil in treatment of fatigue in multiple sclerosis , 2002, Journal of Neurology.

[125]  Bin Liu,et al.  Microglial activation‐mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease , 2002, Journal of neurochemistry.

[126]  D. Souza,et al.  Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes , 2002, Neurochemistry International.

[127]  David Eidelberg,et al.  Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. , 2002, The American journal of psychiatry.

[128]  H. Bading,et al.  Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways , 2002, Nature Neuroscience.

[129]  C. Nemeroff,et al.  Neurobehavioral Effects of Interferon-α in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions , 2002, Neuropsychopharmacology.

[130]  T. Nakano,et al.  Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study , 2002, Palliative medicine.

[131]  K. Sumida,et al.  Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia. , 2002, Hawaii medical journal.

[132]  R. Dantzer,et al.  Cytokine-induced sickness behaviour: mechanisms and implications , 2002, Trends in Neurosciences.

[133]  H. Nagaraja,et al.  Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study , 2002, Journal of neurology, neurosurgery, and psychiatry.

[134]  H. Meltzer,et al.  Increased Depressive Ratings in Patients With Hepatitis C Receiving Interferon-α–Based Immunotherapy Are Related to Interferon-α–Induced Changes in the Serotonergic System , 2002 .

[135]  Andrew J Saykin,et al.  Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  V Kaasinen,et al.  Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. , 2001, Brain : a journal of neurology.

[137]  V Sossi,et al.  A Reversible Tracer Analysis Approach to the Study of Effective Dopamine Turnover , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[138]  G. Goodall,et al.  Acute interferon-α administration modulates sucrose consumption in the rat , 2001, Psychoneuroendocrinology.

[139]  A K Manatunga,et al.  Paroxetine for the prevention of depression induced by high-dose interferon alfa. , 2001, The New England journal of medicine.

[140]  R. Yirmiya.  Depression in medical illness: the role of the immune system. , 2000, The Western journal of medicine.

[141]  J. Bauer,et al.  Prefrontal cortical hypometabolism during low-dose interferon alpha treatment , 2000, Psychopharmacology.

[142]  T. Bottiglieri,et al.  Decreased Homovanilic Acid in Cerebrospinal Fluid Correlates with Impaired Neuropsychologic Function in HIV-1-Infected Patients , 2000, Clinical neuropharmacology.

[143]  T. Kumai,et al.  Effect of interferon-α on tyrosine hydroxylase and catecholamine levels in the brain of rats , 2000 .

[144]  T. Stone.  Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. , 2000, Trends in pharmacological sciences.

[145]  H. Higuchi,et al.  Effect of single intracerebroventricular injection of α-interferon on monoamine concentrations in the rat brain , 2000, European Neuropsychopharmacology.

[146]  M E Newman,et al.  Illness, Cytokines, and Depression , 2000, Annals of the New York Academy of Sciences.

[147]  T. Stone,et al.  Oxidative stress as a mechanism for quinolinic acid‐induced hippocampal damage: protection by melatonin and deprenyl , 1999, British journal of pharmacology.

[148]  M. LaVoie,et al.  Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine , 1999, The Journal of Neuroscience.

[149]  A. Brogi,et al.  Constitutive Expression of Interleukin-1beta (IL-1beta) in Rat Oligodendrocytes , 1999, Biological chemistry.

[150]  J. Weiss,et al.  Astrocyte-derived monocyte-chemoattractant protein-1 directs the transmigration of leukocytes across a model of the human blood-brain barrier. , 1998, Journal of immunology.

[151]  J. Zweier,et al.  Superoxide Generation from Endothelial Nitric-oxide Synthase , 1998, The Journal of Biological Chemistry.

[152]  S. Donnelly.  Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma. , 1998, Oncology nursing forum.

[153]  R. Dantzer,et al.  Cytokines and Sickness Behavior , 1998, Annals of the New York Academy of Sciences.

[154]  J. Cadet,et al.  Invited Review Free radicals and the pathobiology of brain dopamine systems , 1998, Neurochemistry International.

[155]  S. Rivest,et al.  Effect of Acute Systemic Inflammatory Response and Cytokines on the Transcription of the Genes Encoding Cyclooxygenase Enzymes (COX‐1 and COX‐2) in the Rat Brain , 1998, Journal of neurochemistry.

[156]  Taylor Jl,et al.  The effects of interferon-alpha on the production and action of other cytokines. , 1998 .

[157]  B. Brew,et al.  Quinolinic Acid Production by Macrophages Stimulated with IFN-γ, TNF-α, and IFN-α , 1997 .

[158]  K. Yamagata,et al.  Involvement of cyclooxygenase-2 in LPS-induced fever and regulation of its mRNA by LPS in the rat brain. , 1997, The American journal of physiology.

[159]  C. Saper,et al.  Intravenous lipopolysaccharide induces cyclooxygenase 2‐like immunoreactivity in rat brain perivascular microglia and meningeal macrophages , 1997, The Journal of comparative neurology.

[160]  M. Fava,et al.  Folate, vitamin B12, and homocysteine in major depressive disorder. , 1997, The American journal of psychiatry.

[161]  R. Oishi,et al.  Repeated interferon-α administration inhibits dopaminergic neural activity in the mouse brain , 1997, Brain Research.

[162]  K. Schauenstein,et al.  NEUROIMMUNOMODULATION VIA LIMBIC STRUCTURES — THE NEUROANATOMY OF PSYCHOIMMUNOLOGY , 1997, Progress in Neurobiology.

[163]  G. Kreutzberg.  Microglia: a sensor for pathological events in the CNS , 1996, Trends in Neurosciences.

[164]  C. Coe,et al.  Interleukin-1β differentially affects interleukin-6 and soluble interleukin-6 receptor in the blood and central nervous system of the monkey , 1996, Journal of Neuroimmunology.

[165]  N. Rothwell,et al.  Cytokines and fever. , 1996, International archives of allergy and immunology.

[166]  Francesco Scaravilli,et al.  Neuropathology of Early HIV‐1 Infection , 1996, Brain pathology.

[167]  A. Cross,et al.  Fatigue therapy in multiple sclerosis , 1995, Neurology.

[168]  W. Banks,et al.  Passage of cytokines across the blood-brain barrier. , 1995, Neuroimmunomodulation.

[169]  J R Moeller,et al.  Visualizing the evolution of abnormal metabolic networks in the brain using PET. , 1995, Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society.

[170]  Steven F. Maier,et al.  Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication , 1995, Neuroscience Letters.

[171]  I. Moroo,et al.  Immunohistochemistry using antibodies to α-interferon and its induced protein, MxA, in Alzheimer's and Parkinson's disease brain tissues , 1994, Neuroscience Letters.

[172]  J. Bergman,et al.  Observational studies of dopamine D1 and D2 agonists in squirrel monkeys , 1994, Psychopharmacology.

[173]  T. Ishikawa,et al.  The Metabolic Topography of Parkinsonism , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[174]  M. Candito,et al.  High-performance liquid chromatographic measurement of cerebrospinal fluid tetrahydrobiopterin, neopterin, homovanillic acid and 5-hydroxindoleacetic acid in neurological diseases. , 1994, Journal of chromatography. B, Biomedical applications.

[175]  P. Mcgeer,et al.  Expression of MRP14, 27E10, interferon-α and leukocyte common antigen by reactive microglia in postmortem human brain tissue , 1994, Journal of Neuroimmunology.

[176]  P. Sawchenko,et al.  A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[177]  E. Major,et al.  A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. , 1993, Brain : a journal of neurology.

[178]  M. Hart,et al.  Product ion of the cytokines interleukin 1 and 6 by murine brain microvessel endothelium and smooth muscle pericytes , 1993, Journal of Neuroimmunology.

[179]  J. Hubble,et al.  Aromatic L‐Amino Acid Decarboxylase Activity of Mouse Striatum Is Modulated via Dopamine Receptors , 1993, Journal of neurochemistry.

[180]  K. Ganeshaguru,et al.  Effects of interferon-alpha (IFN) on the expression of interleukin 1-beta (IL-1), interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF) in acute myeloid leukemia (AML) blasts. , 1992, Leukemia.

[181]  C. Colton,et al.  Regulation of microglial function by interferons , 1992, Journal of Neuroimmunology.

[182]  V. Levin,et al.  Opioid-dopaminergic mechanisms in the potentiation of d-amphetamine discrimination by interferon-α , 1992, Pharmacology Biochemistry and Behavior.

[183]  E. R. Kloet,et al.  Localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain , 1992, Neuroscience Letters.

[184]  A. Arimura,et al.  Effect of intravenous injection of IL-1 beta on PGE2 levels in several brain areas as determined by microdialysis. , 1992, The American journal of physiology.

[185]  E. Bosmans,et al.  Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining , 1992, Psychological Medicine.

[186]  E. Bosmans,et al.  Depression‐related disturbances in mitogen‐induced lymphocyte responses and interleukin‐1β and soluble interleukin‐2 receptor production , 1991, Acta psychiatrica Scandinavica.

[187]  A. Procter,et al.  Enhancement of Recovery from Psychiatric Illness by Methylfolate , 1991, British Journal of Psychiatry.

[188]  R. Schwarcz,et al.  Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism , 1991, Journal of neurochemistry.

[189]  E. H. Reynolds,et al.  Enhancement of recovery from psychiatric illness by methylfolate , 1990, The Lancet.

[190]  E. Benveniste,et al.  Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta. , 1990, Journal of immunology.

[191]  V. Kostic,et al.  Reduced rapid eye movement sleep latency in patients with parkinson's disease , 1989, Journal of Neurology.

[192]  M. Shin,et al.  Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[193]  C. Saper,et al.  Interleukin-1 immunoreactive innervation of the human hypothalamus. , 1988, Science.

[194]  S. Rapoport,et al.  Kinetics of Neutral Amino Acid Transport Across the Blood‐Brain Barrier , 1987, Journal of neurochemistry.

[195]  M. Reite,et al.  Interferon decreases REM latency , 1987, Biological Psychiatry.

[196]  T Jones,et al.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[197]  R. W. Keane,et al.  Astrocytes produce interferon that enhances the expression of H-2 antigens on a subpopulation of brain cells , 1986, The Journal of cell biology.

[198]  Richard Smith,et al.  Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration , 1985, Clinical pharmacology and therapeutics.

[199]  M. Edelstein,et al.  Biosynthesis of tetrahydrobiopterin by de novo and salvage pathways in adrenal medulla extracts, mammalian cell cultures, and rat brain in vivo. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[200]  Eric M. Smith,et al.  Human leukocyte interferon (HuIFN-α): Potent endorphin-like opioid activity , 1981 .

[201]  H. Harlow,et al.  Effects of reserpine on the social behavior of rhesus monkeys. , 1971, Diseases of the nervous system.

[202]  Andrew H. Miller,et al.  Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior , 2012, Neuropsychopharmacology.

[203]  L. Ginsberg,et al.  L-methylfolate Plus SSRI or SNRI from Treatment Initiation Compared to SSRI or SNRI Monotherapy in a Major Depressive Episode. , 2011, Innovations in clinical neuroscience.

[204]  I. Campbell,et al.  Systemic interferon-alpha regulates interferon-stimulated genes in the central nervous system. , 2008, Molecular psychiatry.

[205]  B. Bogerts,et al.  Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. , 2008, Journal of psychiatric research.

[206]  R. Dantzer,et al.  Named Series: Twenty Years of Brain, Behavior, and Immunity Twenty years of research on cytokine-induced sickness behavior , 2007 .

[207]  G. Pagnoni,et al.  Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. , 2007, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[208]  R. Schwarcz,et al.  Kynurenic acid leads, dopamine follows: A new case of volume transmission in the brain? , 2006, Journal of Neural Transmission.

[209]  Jing-shi Tang,et al.  mu- but not delta- and kappa-opioid receptor mediates the nucleus submedius interferon-alpha-evoked antinociception in the rat. , 2006, Neuroscience Letters.

[210]  P. Hauser,et al.  Can rodents be used to model interferon-alpha-induced depressive symptoms? , 2006, Progress in neuro-psychopharmacology & biological psychiatry.

[211]  B. Brew,et al.  Expression of indoleamine 2,3‐dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons , 2005, Glia.

[212]  Andrew H. Miller,et al.  Neuropsychiatric adverse effects of interferon-alpha: recognition and management. , 2005, CNS drugs.

[213]  Andrew H. Miller,et al.  Neuropsychiatric Adverse Effects of Interferon-α , 2005 .

[214]  Andrew H. Miller,et al.  Cytokines and psychopathology: lessons from interferon-alpha. , 2004, Biological psychiatry.

[215]  M. Reite,et al.  The effect of reserpine and monoamine oxidase inhibitors on paradoxical sleep in the monkey , 2004, Psychopharmacologia.

[216]  R. Schwarcz,et al.  3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease? , 2003, Advances in experimental medicine and biology.

[217]  M. Delong,et al.  Functional neuroanatomy of the basal ganglia in Parkinson's disease. , 2003, Advances in neurology.

[218]  B. Brew,et al.  Expression of the kynurenine pathway enzymes in human microglia and macrophages. , 2003, Advances in experimental medicine and biology.

[219]  D. Musselman,et al.  Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. , 2002, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[220]  H. Meltzer,et al.  Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. , 2002, Journal of clinical psychopharmacology.

[221]  Dennis S. Charney,et al.  Neuropsychopharmacology : The Fifth Generation of Progress , 2002 .

[222]  G. Goodall,et al.  Acute interferon-alpha administration modulates sucrose consumption in the rat. , 2001, Psychoneuroendocrinology.

[223]  T. Stone.  Stone.vp:CorelVentura 7.0 , 2001 .

[224]  T. Nishikawa,et al.  Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha. , 2000, Clinical neuropharmacology.

[225]  T. Kumai,et al.  Effect of interferon-alpha on tyrosine hydroxylase and catecholamine levels in the brain of rats. , 2000, Life sciences.

[226]  H. Anisman,et al.  Anhedonic and anxiogenic effects of cytokine exposure. , 1999, Advances in experimental medicine and biology.

[227]  A. Reichenberg,et al.  Cytokines, "depression due to a general medical condition," and antidepressant drugs. , 1999, Advances in experimental medicine and biology.

[228]  M. Maes,et al.  Major depression and activation of the inflammatory response system. , 1999, Advances in experimental medicine and biology.

[229]  A. Sluzewska,et al.  Indicators of immune activation in depressed patients. , 1999, Advances in experimental medicine and biology.

[230]  Donald W. Miller,et al.  Immunobiology of the blood-brain barrier. , 1999, Journal of neurovirology.

[231]  R. Dantzer,et al.  Correction to: Cytokines, “Depression Due to A General Medical Condition,” and Antidepressant Drugs , 1999 .

[232]  S. Grossberg,et al.  The effects of interferon-alpha on the production and action of other cytokines. , 1998, Seminars in oncology.

[233]  H. Kuroiwa,et al.  [Parkinsonism in a patient receiving interferon alpha therapy for chronic hepatitis C]. , 1997, Rinsho shinkeigaku = Clinical neurology.

[234]  Y. Kataoka,et al.  Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. , 1997, Brain research.

[235]  B. Brew,et al.  Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[236]  N. Rothwell,et al.  Cytokines and their receptors in the central nervous system: physiology, pharmacology, and pathology. , 1996, Pharmacology & therapeutics.

[237]  R. Dantzer,et al.  Lipopolysaccharide induces sickness behaviour in rats by a vagal mediated mechanism. , 1994, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[238]  V. Kostic,et al.  Sleep EEG in depressed and nondepressed patients with Parkinson's disease. , 1991, The Journal of neuropsychiatry and clinical neurosciences.

[239]  A. Arimura,et al.  Involvement of organum vasculosum of lamina terminalis and preoptic area in interleukin 1 beta-induced ACTH release. , 1990, The American journal of physiology.

[240]  A. Dunn,et al.  Systemic interleukin-1 administration stimulates hypothalamic norepinephrine metabolism parallelling the increased plasma corticosterone. , 1988, Life sciences.

[241]  R. Riccardi,et al.  Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: comparison of intravenous, intramuscular, and intraventricular delivery. , 1985, Cancer drug delivery.

[242]  E. M. Smith,et al.  Human leukocyte interferon (HuIFN-alpha): potent endorphin-like opioid activity. , 1981, Biochemical and biophysical research communications.

[243]  Transforming growth factor- (cid:1) directly augments histidine decarboxylase and vesicular monoamine transporter 2 production in rat enterochromaffin-like cells , 2022 .